Finance

Lists
MOLN:NASDAQ
Molecular Partners AG
$4.35
+6.88%
(+0.28) 1D
Sep 3, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MOLN...
Open
$4.35
High
$4.35
Low
$4.35
Mkt. cap
180.27M
Avg. vol.
1.09K
Volume
0.00
52-wk high
$5.36
52-wk low
$3.53
EPS
-$1.69
Beta
1.02
Shares outstanding
40.38M
No. of employees
134
Open
$4.35
High
$4.35
Low
$4.35
Mkt. cap
180.27M
Avg. vol.
1.09K
Volume
0.00
52-wk high
$5.36
52-wk low
$3.53
EPS
-$1.69
Beta
1.02
Shares outstanding
40.38M
No. of employees
134
News stories
From web sources and news partners
Profile
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
About Molecular Partners AG
CEO-
Employees134
Founded2004
Headquarters-
SectorBiotechnology
Analyst ratings
Based on 2 analysts giving stock ratings to MOLN in the past 3 months
Buy
Buy
2
Hold
0
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for MOLN in the last 3 months.
Highest
Current $4.35
$13.00 (+198.85%)
Average
$12.50 (+187.36%)
Lowest
$12.00 (+175.86%)
Analyst
Recommendation
Action
Price target
Projected
Date
Charles Zhu
LifeSci Capital
Buy
Maintained
$12.00
+175.9%
08/25/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
$13.00
+198.9%
07/06/2026
Jonathan Chang
Leerink Partners
Buy
Reiterated
-
-
06/02/2026
William Maughan
Clear Street
Buy
Maintained
$8.00
+83.9%
03/13/2026
Last report
Aug 25, 2026
Fiscal period
Q2 2026
EPS / Est. (CHF)
-CHF 0.35 / -CHF 0.35
0.00%miss
Revenue / Est. (CHF)
- / 0.00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in CHF
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CHF
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
8.33M
8.18M
9.44M
9.61M
Cost of revenue
8.33M
8.18M
9.44M
9.61M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.60M
4.48M
4.00M
3.98M
Operating expense
3.60M
4.48M
4.00M
3.98M
Total operating expenses
11.93M
12.67M
13.44M
13.59M
Operating income
-11.93M
-12.67M
-13.44M
-13.59M
Other non operating income
-2.00K
-5.00K
-4.00K
-5.00K
EBT including unusual items
-11.84M
-12.64M
-13.14M
-13.56M
EBT excluding unusual items
-11.72M
-12.69M
-13.14M
-13.56M
Income tax expense
-
4.00K
-
-
Effective tax rate
-
-0.03%
-
-
Other operating expenses
-
-
-
-
Net income
-11.84M
-12.65M
-13.14M
-13.56M
Net profit margin
-
-
-
-
Earnings per share
-0.33
-0.36
-0.35
-0.35
Interest and investment income
366.00K
234.00K
176.00K
38.00K
Interest expense
-3.00K
-6.00K
-7.00K
-6.00K
Net interest expenses
363.00K
228.00K
169.00K
32.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-11.40M
-12.44M
-12.94M
-13.11M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google apps